Alectinib in Combination With Nivolumab in the Treatment of Recurrent or Refractory HCC Patients Guided With Serum RNase1 and Tumor Expression of PD-L1

NCT06354387 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

5

Enrollment

OTHER

Sponsor class

Conditions

Hepatocellular Carcinoma

Interventions

DRUG: Alectinib (Alecensa), Nivolumab (Opdivo)

Sponsor

China Medical University Hospital